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Potential interventions for the prevention of
childhood pneumonia in developing countries:
a meta-analysis of data from field trials to
assess the impact of vitamin A supplementation
on pneumonia morbidity and mortality*
The Vitamin A and Pneumonia Working Group1
Reported are the results of a meta-analysis (12 large-scale field trials in seven countries) of the impact
of vitamin A supplementation on pneumonia morbidity and mortality, undertaken as part of a wider
review process of a range of possible potential interventions for the prevention of childhood pneumonia.
The summary estimate of the relative risk for the impact of vitamin A supplementation on pneumonia
incidence was 0.95 (95% confidence interval (Cl) = 0.89, 1.01), and for pneumonia mortality, 0.98 (95%
Cl = 0.75, 1.28). This is in marked contrast to the substantial impact of vitamin A supplementation on
all-cause mortality (combined rate ratio (RR) = 0.77, 95% Cl = 0.71, 0.84), and on diarrhoea-specific
and measles-specific mortality. There was no evidence for a differential impact on pneumonia mortality
by age. Since the majority of pneumonia deaths occur in the first year of life, we complemented the
paucity of data on pneumonia-specific mortality among this age group with a detailed examination of all-
cause mortality among infants. The mortality reduction in the 6-11-month age group was consistent
with that observed for older age groups (RR = 0.69; 95% Cl = 0.54, 0.90), but there was no reduction
for 0-5-month-olds (RR = 0.97; 95% Cl = 0. 73, 1.29).
' This publication is part of a series of reviews of potential inter-
ventions for the prevention of childhood pneumonia among
under-5-year-olds in developing countries, being carried out by
the WHO Programme for the Control of Acute Respiratory Infec-
tions (WHO-ARI) and the Maternal and Child Epidemiology Unit,
London School of Hygiene and Tropical Medicine (MCEU-
LSHTM), with support from the United Kingdom Overseas Devel-
opment Administration, WHO, and UNICEF. The aim is to identi-
fy selected nutritional, environmental, behavioural and vaccine
interventions that can be expected to have a significant impact
on pneumonia morbidity and mortality in children.
Vitamin A deficiency is one of 22 risk factors that have
been reviewed. The meta-analysis is a more detailed follow-up
to an initial review of the literature and biological plausibility
which was carried out by A. Tomkins and K. Southwick, Institute
of Child Health, London, as part of the general activities of the
review series. It was undertaken by a working group that includ-
ed the principal investigators of all the large-scale field studies
which had been completed up to January 1993. Analyses were
carried out within the individual studies using data analysis pro-
tocols prepared by LSHTM and agreed at a meeting convened
by WHO-ARI in Geneva in November 1992. The results were
Reprint No. 5640
summarized and conclusions agreed at a second meeting in
Geneva in February 1993 (See: Vitamin A supplementation and
childhood pneumonia: report of a meeting, Geneva, 1-3 Febru-
ary 1993. Unpublished document WHO/CDR/93.2, 1993).
1 The composition of the working group was as follows: ACEH
(Indonesia) study: A. Sommer; MADURAI (India) study: L. Rah-
mathullah, B. Underwood, and R. Milton; HYDERABAD (India)
study: V. Reddy; SARLAHI (Nepal) study: K. West; JUMLA
(Nepal) study: N. Daulaire, T. Stukel; SUDAN study: G. Herrera;
HAITI study: S. Stansfield; Ghana VAST (survival study): D.
Ross; Ghana VAST (health study): B.R. Kirkwood, P. Arthur,
and S. Morris; MORVITA (Indonesia) study: C. Kjolhede, M.
Dibley; BAHIA (Brazil) study: M. Barreto; DELHI (India) study:
M.K. Bhan; and WHO-ARI: S. Gove.
The meta-analysis was coordinated and the manuscript
prepared by P. Arthur, B.R. Kirkwood, and S. Morris, London
School of Hygiene and Tropical Medicine, Keppel Street, London
WC1 E 7HT, England; and by S. Gove, Programme for the Con-
trol of Acute Respiratory Infections, World Health Organization,
1211 Geneva 27, Switzerland. Requests for reprints should be
sent to Dr Gove at the latter address. Other correspondence
should be sent to Professor Kirkwood at the London School of
Hygiene and Tropical Medicine.
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Background
Several histopathological changes to epithelial tissue
following vitamin A depletion have been described
which suggest that vitamin A deficiency (VAD)
might predispose to respiratory infections. Wide-
spread keratinization of the epithelium in the nose,
sinuses, larynx, trachea and bronchi in rats (1),
autopsy findings of keratinizing metaplasia of the
respiratory tract in children (2), and electron micro-
scopy studies showing early, rapid squamous meta-
plasia with loss of ciliary and goblet cells in rats (3)
have all established that vitamin A is essential to the
normal growth and differentiation of respiratory tract
epithelium. Reduced lysozyme activity that responds
to vitamin A therapy has also been observed in chil-
dren (4). These changes result in a reduction of the
trapping and clearing of airborne pathogens and irri-
tants, and an increase of bacterial binding to respira-
tory epithelial cells (5). The physical and biological
integrity of epithelial tissue, which is the first barrier
to infection, is thus compromised in vitamin A defi-
ciency and this would be expected to result in an
increase in the incidence of respiratory infections.
Abnormalities in systemic immunity also occur.
These include changes in the mass and maturation of
lymphoid tissue, abnormal production of immune
response regulators, reduced natural killer cell activ-
ity, and abnormal phagocyte and cytotoxic function
and antibody production (6-9). Although the changes
are less clear and varied for the different components
of the immune system, the net effect appears to be a
depression of the specific response to infection once
the epithelial barriers have been breached.
Consistent with these results are findings from
longitudinal field observational studies that children
with VAD have an increased risk of acute respiratory
infections (10-12). Clinical studies have also shown
that the severity of illness and case fatality are
reduced when vitamin A is administered to children
with measles (13-16). It has therefore been hypothe-
sized that improving the vitamin A status of children
who are vitamin A deficient should lead to a reduc-
tion in respiratory morbidity and mortality. If this
proves to be the case, promoting vitamin A pro-
grammes would be a potential strategy for the con-
trol of childhood pneumonia, which alone accounted
for nearly 3.6 million out of the 12 million childhood
deaths that occurred in developing countries in 1990
(17).
In an initial review in February 1992, we exam-
ined the relationship between VAD and childhood
pneumonia and the impact of vitamin A supplemen-
tation on pneumonia. At that time there were few
published studies on this topic. Those studies that
had been carried out had primarily evaluated the
impact of vitamin A on overall childhood mortality,
and contained very little information on pneumonia-
specific morbidity and mortality. Data from six field
trials in Indonesia, India, and Nepal were reviewed
(18-23), which showed large reductions in overall
childhood mortality following supplementation with
vitamin A.
A large beneficial impact on all-cause mortality
cannot be expected without an impact on the leading
causes of childhood deaths, i.e., pneumonia and diar-
rhoea, which together account for more than 60% of
all childhood deaths in developing countries. How-
ever, although deaths due to diarrhoea and measles
were reduced in these studies, there was no impact
on deaths due to pneumonia. The data from the stud-
ies were not disaggregated by age, and an impact on
pneumonia could have been missed because infants
were underrepresented. Nearly 75% of nonprimary
measles and pertussis pneumonia deaths among pre-
school-age children occur in infants - up to 58%
before 6 months of age. Except for the two studies in
Nepal, all the others were of children above 6
months of age (6-72 months), and individual studies
had covered insufficient numbers of children in the
most vulnerable age group to detect an impact on
pneumonia. Data from a set of more recent field
studies that were completed in 1991, including four
studies that had conducted a detailed evaluation of
the impact on morbidity and one that included young
infants, permitted a more detailed examination of
the relationship between VAD and childhood pneu-
monia.
We have reviewed the impact of vitamin A sup-
plementation on pneumonia morbidity and mortality
using a meta-analysis of the pooled data from large-
scale field trials completed by January 1993. The
objectives were to obtain estimates of the effect of
supplementation on pneumonia mortality and to
examine whether vitamin A supplementation has any
impact (positive or negative) on the incidence and
prevalence of childhood pneumonia. Of particular
interest, was the impact if any, among infants, the
group at highest risk from pneumonia mortality. The
findings of the review are described in this article.
Methods
The principal investigators of 12 completed large-
scale field trials (published and unpublished) that
collected data on acute respiratory infection (ARI)
morbidity and/or mortality contributed data to the
review. Seven studies were conducted in Asia (India
(3 studies), Indonesia (2), Nepal (2)); three in Africa
(Ghana (2), Sudan); and one each in Brazil and Haiti.
The study sites differed in terms of their affluence
WHO Bulletin OMS. Vol 73 1995610
Vitamin A supplementation and pneumonia: a meta-analysis
and indicators of health, nutritional status and vita-
min A profile - from areas of relatively high
affluence and zero prevalence of xerophthalmia
(Brazil) to extremely deprived areas with very high
rates of xerophthalmia (JUMLA, in Nepal; MADU-
RAI, in India).
The main characteristics of the sites and the
study design features are summarized in Table 1. All
the trials used oral doses of vitamin A, ranging from
weekly low doses (MADURAI) to 6-monthly high
doses (ACEH, HYDERABAD and SUDAN). In two
of the trials (JUMLA and DELHI) only a single
high-dose supplement was administered, with a rela-
tively short period of follow-up of children (5
months and 3 months, resp.). The four trials that pri-
marily evaluated morbidity end-points (BAHIA,
DELHI, VAST-CHS and MORVITA) were all ran-
domized at the level of the individual child, and
those that evaluated the impact on mortality (ACEH,
HYDERABAD, MADURAI, JUMLA, SARLAHI,
SUDAN and VAST-CSS) were randomized on larg-
er units, such as households, villages, clusters of vil-
lages, or other administrative or geographical divi-
sions. The HAITI study was similar in design to the
mortality studies, but only provided data on morbid-
ity. All of these studies were field trials with supple-
mentation of the general child population, except for
the DELHI trial, which was restricted to children with
acute diarrhoea who were recruited from a clinic.
All of the trials included children aged .6
months, except for HYDERABAD and DELHI (.12
months of age), but only two (SARLAHI and
JUMLA) systematically included infants under 6
months of age. The SARLAHI study provided 16
months' data on young infants out of a total of 24
months' follow-up (data cleaning for the last few
months of the trial was still in progress when the
meta-analysis was performed).
A detailed protocol for standardized data analy-
sis (available on request) was prepared in consulta-
tion with the principal investigators and standard
definitions were agreed. In some cases these differed
slightly from those used in the primary analyses of
the individual studies. Pneumonia was defined as
reported cough plus fast breathing, using a respira-
tory rate cut-off of >50 breaths per minute for in-
fants and >40 breaths per minute for 1-4-year-olds.
In the JUMLA study, however, a single respiratory
rate cut-off of >50 breaths per minute was used for all
children, and chest indrawing was also a sufficient
condition for the diagnosis of pneumonia.
An episode was defined as beginning on the first
day of coughing and either measured fast breathing
or reported rapid breathing, and ending on the last
day of the same combination of symptoms. A mini-
mum of 14 days free from this symptom combination
was required to define a new episode. If symptoms
recurred in less than 14 days, those days of symp-
toms as well as the intervening symptom-free days,
were considered to be part of the immediately pre-
ceding episode. Each episode was attributed to the
age group the child was in when the episode started,
and each child-week of follow-up was attributed to
the age group to which the child belonged. Child-
weeks of follow-up included all weeks when the
child was seen by the field worker, as well as the
weeks when the child was temporarily absent from
home, but did not include periods when the child had
moved away from the study area. Weeks of illness
were not subtracted from the total weeks of follow-
up. Asymptomatic days within episodes of pneumo-
nia were not counted as positive days for the purpose
of prevalence estimates.
Data on pneumonia-specific mortality were
available from five out of the seven mortality studies
and were based on cause of death obtained by verbal
postmortem. Each death was attributed to the age
group the child was in at the time of his/her death,
and follow-up time was distributed between the vari-
ous age groups the child passed through in the
course of the study.
Combined estimates of the effect of vitamin A
supplementation on pneumonia incidence and pneu-
monia mortality were obtained by Poisson regression
using the number of deaths and child-years of
follow-up in the two treatment groups as reported
from each study. Where randomization was not at the
individual level, the regression was weighted to
allow for within-cluster homogeneity, using design
effects (see Table 4) taken from the study by Beaton
et al.a The results were not particularly sensitive to
the precise choice of weightings. For the JUMLA
study, in which 16 panchayats (geographical and
administrative subdivisions) were sampled using a
nonrandom procedure for allocation to the two treat-
ment groups, adjustment factors were incorporated
to accommodate substantial pre-trial differences be-
tween the vitamin A and placebo clusters. These fac-
tors were calculated using a longitudinal analysis
incorporating pre-supplementation, post-supplemen-
tation and during supplementation periods by treat-
ment group interaction term (T. Stukel, personal
communication, 1993). It was not possible to adjust
for within-individual clustering of pneumonia epi-
sodes in the morbidity analysis, and the quoted P-
values for incidence rate ratios may therefore be
underestimates.
a Beaton GH et al. Effectiveness of vitamin A supplementation
in the control of young child morbidity and mortality in develop-
ing countries. Report submitted to Canadian International Devel-
opment Agency, December 1992.
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Table 1: Characteristics of studies included in the meta-analysis
Study/(ref.)
BAHIA, Brazil
DELHI, India
MORVITA, Indonesia
VAST-CHS,
Ghana (24)
HAITI (25)
ACEH, Indonesia (23)
HYDERABAD,
India (22)
JUMLA, Nepal (18)
MADURAI, India (21)
SARLAHI, Nepal (19)
SUDAN (26)
VAST-CSS,
Ghana (24)
Sample size/ Vitamin A status
age group at baselinea
1 240/6-48 months 00o xerophthalmia
(57 839 child-weeks)b 50% ret <0.70 pg/I
900/12-60 months 3.8% XN + X1B
1400/6-48 months 0% xerophthalmia
(78 202 child-weeks)b 59% ret <0.70 pg/I
1 455/6-59 months
(61 602 child-weeks)b
1.4% XN
0.2% X1B
15.3% ret <0.35 pg/l
72% ret <0.70 pg/l
11 124/6-83 months 0.1% X2+X3+XS
25 200/12-71 months
14 082/12-59 months
7 197/1-59 months
0.7% XN
2.7% X1B
2% XN
4% X1B
4.7% XN
(127 135 child-weeks)b 8.2% X1B
15 419/4-72 months 3.7% XN
(670 740 child-weeks)b 7.2% Xl B
19% ret <0.35 pg/l
36% ret <0.70 pg/l
9 000/0-72 months 2.8% XN+X1 B
(31 416 child-years)b
28 753/9-72 months 0.7 XN
2.7% X1B
21 906/6-95 months 1% XN
(33 287 child-years)b 0.02% Xl B
14% ret <0.35 pg/I
58% ret <0.70 pg/l
Dosing
regimen
4-Monthly
(x 3)
Single
dose
4-Monthly
(x 6)
4-Monthly
(x 3)
4-Monthly
(x 3)
6-Monthly
(x 2)
6-Monthly
(x 2)
Single
dose
Weekly
(x 52)
4-Monthly
Surveillance
ARI
data
Home visits Pneumonia
(x3 per week); referral incidence +
if RR>40 minc prevalence
Home visits
(x3 per week)
for 90 days
48-Hour home
visits; referral if
RR>35 minc
Weekly home visits;
clinic referral for
probable ALRI
4-Monthly home
visits
Cross-sectional
surveys at start and
9-13 months later
3-Monthly home
visits
Case detection;
death registration;
verbal postmortem
Weekly home visits;
verbal postmortem
4-Monthly visits;
verbal postmortem
6-Monthly (x3) 6-Monthly visits;
verbal postmortem
4-Monthly
(x 6)
4-Monthly home
visits; verbal
postmortem
Pneumonia
incidence +
prevalence
Pneumonia
incidence +
prevalence
Pneumonia
incidence +
prevalence
2-Weeks of ARI
symptoms
Weekly
prevalence
of cough
4-Weeks of
coughing
Pneumonia
incidence +
mortality
Pneumonia
mortality
Weekly prevalence
of ARI symptoms;
pneumonia mortality
Weekly prevalence
of ARI symptoms;
pneumonia mortality
2-Weeks of ARI
symptoms; ALRI
mortality
a XN = night blindness; X1B = Bitot's spots; X2 = conjunctival xerosis; X3 = keratomalacia; XS = corneal scar; ret = serum retinol
levels.
b Data in parentheses are person-time of follow-up.
c RR = measured respiratory rate (count per minute).
Results
Impact on pneumonia morbidity
Incidence of pneumonia. The number of episodes of
pneumonia and the child-weeks of observation in the
detailed morbidity studies and in the JUMLA study
are shown in Table 2, as well as point estimates of
the impact of supplementation. Only the rate ratio for
JUMLA (0.77) showed a significant impact. The rate
ratios in the other studies ranged from 0.92
(VAST-CHS) to 1.14 (MORVITA). The summary
estimate of the impact on pneumonia incidence using
data from all the studies was 0.95 (95% confidence
interval (CI) = 0.89, 1.01); and 0.99 (95% CI = 0.92,
1.06) if the JUMLA study was excluded. The same
analyses were repeated using a high breathing rate
cut-off (50 breaths per minute) for all children,
regardless of age, as was done in the JUMLA study.
This resulted in a substantial decrease in the number
of pneumonia episodes observed, especially in
children over 2 years of age, but the conclusions
regarding the impact of vitamin A supplementation
remained unchanged.
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Table 2: Impact of vitamin A supplementation on pneumonia incidencea
Vitamin A Placebo
No. of child- Rate No. of No. of child- Rate
weeks (per annum) episodes weeks (per annum)
402 38 345
544 29 000
166 5 452
496 30 520
797 67 520
0.55
0.98
1.58
0.85
344 37 366
557 28 839
174 5 424
530 30 115
0.61 1 047
1 605
2 623
59 615
101 744
162 541
0.48
Rate ratio
1.14
(0.99-1 .32)b
1.00 0.97
(0.86-1.09)
1.67 0.95
(0.77-1.17)
0.92 0.92
(0.82-1.04)
0.91 0.77
(0.66-0.89)
Q.9ge
(0.92-1.06)
0.95e
(0.89-1.01)
a Tests for heterogeneity: (excluding JUMLA) X2 test = 5.13, 3 degrees of freedom, P = 0.161; (including JUMLA) x2 = 14.05, 4
degrees of freedom, P = 0.007.
b Figures in parentheses are the 95% confidence intervals.
c Estimates corrected for design effect and baseline differences between vitamin A and placebo groups.
d Summary of studies (JUMLA excluded).
e Mantel-Haenszel weighted rate ratio.
I Summary of studies (JUMLA included).
The age-specific estimates for the detailed mor-
bidity studies are shown in Fig. 1. There was a slight
trend with age, with a possible detrimental impact on
pneumonia incidence among 6- 1 -month-olds and a
possible beneficial impact on 48-59-month-olds.
This trend was apparent to some degree in each of
the four studies, but was not statistically significant.
The confidence intervals in each of the age groups
overlapped unity, even when the data were pooled
across the studies. Most of the increased risk in the
youngest age group was contributed by the data from
the MORVITA study. The JUMLA data could not be
disaggregated using the same age groupings, and
were therefore analysed separately. There was a
somewhat more pronounced trend with age; the rate
ratio declined from 0.87 (95% CI = 0.72, 1.04) for
the 3-1 1-month age group, to 0.73 (95% CI = 0.57,
0.93) for the 12-23-month age group, to 0.67 (95%
CI = 0.52, 0.87) for the 24-59-month age group.
Fig. 2 shows the age-specific estimates of the
impact of vitamin A supplementation on pneumonia
incidence as defined by a combination of cough plus
maternally reported rapid breathing (VAST-CHS
and MORVITA studies) or cough, cold and fever
plus rapid breathing or chest indrawing (MADURAI
study). There was discordance between the positive
impact reported by the VAST-CHS study and the
detrimental impact reported by the other two studies.
There was strong evidence of heterogeneity of effect
between the different studies, and thus no attempt
was made to summarize the results in a single esti-
mate of the impact of vitamin A supplementation.
Prevalence of pneumonia. Two sources of data on
the prevalence of pneumonia were available: daily
prevalence data from the studies with intensive mor-
bidity surveillance; and period prevalence data from
the remaining studies. In the morbidity studies, in
order to adjust for within-child clustering of illness
episodes, prevalences were calculated for each child
and for each dosing round separately, and the mean
Fig. 1. Impact of vitamin A supplementation on pneu-
monia incidence, based on cough plus measured
raised breathing rate.
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Fig. 2. Impact of vitamin A supplementation on pneu-
monia incidence, based on cough plus maternal report-
ing of rapid breathing.
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prevalences were compared for the vitamin A and
placebo groups. This analysis produced a pattern of
age-specific impacts for prevalence (as defined by
cough plus raised respiratory rate) identical to that
shown for pneumonia incidence in Fig. 1. The data
for the MORVITA and DELHI studies, however,
displayed stronger negative impacts on the preva-
lence of pneumonia among the youngest age groups
than seen for incidence, with a rate ratio as high as
1.73 in the youngest age group for the MORVITA
study (P = 0.08). Nevertheless, overall, there was no
suggestion of an important impact on pneumonia
prevalence over the age range 6-59 months.
Two of the mortality studies also contributed
data on the combination of cough plus (reported)
rapid breathing. One-week-period prevalence data
from the SARLAHI study collected 4 months after
the last dose of vitamin A showed no impact in any
age group. Two-week-period prevalence data from
the HAITI study collected 2-6 weeks after the last
scheduled dose, however, showed 20-25% increases
in the risk of cough plus rapid breathing for most age
groups, reaching statistical significance when all the
age groups were combined.
The findings on the impact of supplementation
on the prevalence of cough, and the combination of
cough plus (reported) fever were also examined. The
overall vitamin A:placebo ratio for the occurrence
of cough was 0.99, and none of these studies sug-
gested any impact-beneficial or deleterious - of
vitamin A supplementation on the combination of
cough plus fever.
Impact on pneumonia-specific mortality
There were clear differences in the verbal postmor-
tem instruments applied, but the data were accepted,
as provided by the various studies. A total of 296
pneumonia deaths were reported from five mortality
trials. The rate ratios for pneumonia-specific mortali-
ty for the various studies and the summary estimate
of the impact of supplementation for all the studies
are shown in Table 3. The estimates are also contras-
ted with the effect estimates obtained for the impact
on all-cause mortality.b The impact of vitamin A
supplementation on pneumonia-specific mortality
varied from a 57% decrease for the SUDAN study to
a 10% increase for the SARLAHI and VAST-CSS
studies, although confidence intervals included unity
in all cases. However, the variation observed is not
more than might reasonably be expected by chance if
the true impact of vitamin A supplementation were
uniform across study sites, and the pooled estimate
of the effect on pneumonia mortality revealed no dif-
ference between the vitamin A and placebo groups
(rate ratio (RR) = 0.98; 95% CI = 0.75, 1.28).
In four of the five studies considered, vitamin A
supplementation had a markedly less protective
effect on pneumonia mortality than on all-cause mor-
tality. Indeed, in two of these studies (VAST-CSS
and SARLAHI), a possibly detrimental effect on
pneumonia mortality coexisted with a positive
impact on all-cause mortality. There was an anomaly
in the results from the SUDAN study, where an
apparently large positive impact on pneumonia
deaths was observed (RR = 0.43) despite an absence
of impact on all-cause mortality (RR = 1.04).
The summary rate ratio from all five studies was
very close to unity (0.98; 95% CI = 0.75-1.28). Age-
specific estimates showed no evidence of a differen-
tial impact by age. The summary rate ratio was 0.96
(95% CI = 0.64, 1.45) among infants aged 1-11
months; 0.91 (95% CI = 0.55, 1.51) among children
aged 12-23 months; and 1.07 (95% CI = 0.65, 1.78)
among those aged 24-59 months. However, since
most pneumonia deaths occur in infancy, this age
group was examined in greater detail. Table 4 shows
the number of pneumonia deaths and child-years of
follow-up for the 0-5-month and 6-11-month age
groups. Rate ratios of 0.88 and 1.08, respectively,
were observed, although confidence intervals were
very wide since there were only just over 50 deaths
in each age group.
Since respiratory illness is such an important
cause of death in infants, the paucity of data on pneu-
monia-specific mortality in this age-group was com-
plemented by re-examining the all-cause mortality
data in infants (Table 5). The mortality reduction for
the 6-1 1-month age group was consistent with that
observed for the older age groups (RR = 0.69; 95%
bSee footnote a, p. 611.
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Table 3: Comparison of the impact of vitamin A supplementation on under-5-year-old pneumonia-specific mortality
and on overall mortalitya
Pneumonia-specific All-cause
Vitamin A Placebo mortality mortality
No. of Mortality No. of Mortality
No. of child- rate No. of child- rate Rate Design
Study deaths years (per 1000) deaths years (per 1000) ratio effectb Rate ratioc
JUMLA 18 1 441 12.5 18 1 274 14.1 0.88 1.416 (0.38-2.05)d 0.74; 0.55-1.01e
MADURAI 2 5 320 0.4 3 5 240 0.6 0.66 1.329 (0.08-5.19) 0.50; 0.34-0.75
SARLAHI 77 17 867 4.3 68 17 339 3.9 1.10 1.187 (0.77-1.57) 0.71; 0.56-0.89
SUDAN 6 15 223 0.4 14 15 162 0.9 0.43 1.000 (0.16-1.19) 1.04; 0.81-1.34
VAST-CSS 47 11 988 3.9 43 12 116 3.5 1.10 2.003 (0.61-1.97) 0.80; 0.70-0.93
Summary 150 51 839 146 51 131 0.98' (0.75-1.28) 0.77; 0.71-0.84
a Test for heterogeneity of effect between studies: x2 test = 3.938, 4 degrees of freedom, P >0.2.
bEmpirical design effect; see footnote a, p. 611.
cSee footnote a, p. 611.
dFigures in parentheses are the adjusted 95% confidence intervals.
eFigures in italics are the 95% confidence intervals.
IMantel-Haenszel weighted rate ratio, adjusted for design effects.
CI = 0.54, 0.90), but no reduction was observed for
the 0-5-month age group (RR = 0.97; 95% CI =
0.73, 1.29).
Discussion
The data from the studies we have reviewed indicate
that supplementation with vitamin A has no consis-
tent overall protective or detrimental effect on pneu-
monia-specific mortality in children aged between 6
months and 5 years of age. This is in contrast to the
demonstrated impact of vitamin A supplementation
on all-cause mortality, and on diarrhoea-specific and
measles-specific mortality. In all of the studies
examined, the impact on pneumonia mortality was
different from that on all-cause mortality. Although
Table 4: Impact of vitamin A supplementation on pneumonia-specific mortality among infants
Vitamin A Placebo
No. of No. of child- No. of No. of child- Rate Design
Study deaths years deaths years ratio effecta
Age group: 0-5 months
JUMLA 2 118.2 5 111 0.38 1.416
MADURAI 0 17.5 0 17.8 - 1.329
SARLAHlb 28 1 748 28 1 670 0.96 1.187
SUDAN 0 5 0 2.5 - 1.000
VAST-CSS 0 8 0 10 - 2.003
Summary 30 1 896.7 33 1 811.3 0.88
(0.51-1 .51 )c
Age group: 6-11 months
JUMLA 5 173.1 7 146.9 0.61 1.416
MADURAI 0 193.4 0 190.8 - 1.329
SARLAHI 12 1 789 11 1 690 1.03 1.187
SUDAN 0 405.5 0 436 - 1.000
VAST-CSS 14 765 8 809 1.85 2.003
Summary 31 3 325.7 26 3 272.5 1.08
(0.57-2.03)
a Empirical design effect; see footnote a, p. 611.
b Based on the first 16 months' data out of a total of 24 months' follow-up.
c Figures in parentheses are the 95% confidence intervals.
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Table 5: Impact of vitamin A supplementation on all-cause mortality among infants
Vitamin A Placebo
No. of No. of child- No. of No. of child- Rate Design
Study deaths years deaths years ratio effecta
Age group: 0-5 months
JUMLA 20 120.2 19 112.9 0.99 1.416
MADURAI 0 17.5 0 17.8 - 1.329
SARLAHlb 98 1 748.0 96 1 670.0 0.97 1.187
SUDAN 0 5.0 0 2.5 - 1.000
VAST-CSS 0 8.0 0 10.0 - 2.003
Summary 118 1 884.7 116 1 797.2 0.97
(0.73-1.29)c
Age group: 6-11 months
JUMLA 24 179.3 41 157.2 0.61 1.416
MADURAI 2 193.4 7 190.8 0.28 1.329
SARLAHI 43 1 789.0 68 1 690.0 0.60 1.187
SUDAN 1 405.5 0 436.0 ? 1.000
VAST-CSS 86 765.0 94 809.0 0.97 2.003
Summary 156 3 320.5 210 3 272.7 0.69
(0.54-0.90)
a Empirical design effect; see footnote a, p. 611.
b Based on the first 16 months' data out of a total of 24 months' follow-up.
c Figures in parentheses are the 95% confidence intervals.
the small number of pneumonia deaths makes it un-
likely that a significant difference between the impact
on pneumonia mortality and that on mortality from
other causes can be demonstrated in any individual
study, the consistency of this relationship is striking.
In the Sudan study, there was a large impact on
deaths associated with "shortness of breath" despite
the absence of an impact on all-cause mortality. This
result however, needs to be interpreted with caution:
shortness of breath is a very nonspecific symptom
for pneumonia, and accounted for far fewer deaths
(<10%) than would be expected to be attributed to
pneumonia in such a population.
The lack of impact of vitamin A supplementa-
tion on pneumonia-specific mortality was probably
not because of misclassification of pneumonia deaths
due to problems associated with the measurement
instrument (verbal postmortem). The across-studies
consistency in the impact on specific causes of
death, despite possible differences in the assignment
of cause of death in the various studies, makes this
an unlikely explanation for the results. A nonsystem-
atic misclassification of cause of death would be
expected to displace the estimate of the impact of
supplementation on pneumonia deaths towards that
of the impact on all-cause mortality, not towards
a rate ratio of unity. This was observed in the
SARLAHI study, when a less specific definition of
pneumonia-associated deaths was used. Furthermore,
similar verbal postmortem instruments have been suc-
cessfully used in evaluating the impact of other
interventions, e.g., pneumonia case management.
The results of this analysis are consistent with
those of a previous review of the effectiveness of
vitamin A supplementation on all-cause mortality in
children over 6 months of age,c which also examined
the impact on respiratory morbidity and mortality.
Six out of the eight field studies included in the last-
mentioned review demonstrated a large impact of
vitamin A interventions on overall childhood mortal-
ity (18-21, 23, 24), and a meta-analysis yielded a
23% summary estimate of effect (RR = 0.77; 95%
Cl = 0.71, 0.84).c All the studies that recorded the
cause of death showed an impact on deaths due to
diarrhoea (summary estimate: RR = 0.71; 95%
CI = 0.57, 0.88) and measles (summary estimate:
RR = 0.46; 95% CI = 0.22, 0.98), but showed no
impact on pneumonia mortality. Similarly, no impact
on pneumonia morbidity was demonstrated.
There are insufficient data for infants aged under
6 months to make any judgement about the risk of
c See footnote a, p. 61 1.
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pneumonia-specific mortality among this age group.
The meta-analysis carried out by Beaton et al.
derived a 23% summary estimate of the impact on
all-cause mortality in young infants (RR = 0.77; 95%
CI = 0.38, 1.54), but noted that the data were scanty
and the result was not statistically significant.d This
is in contrast to the estimated impact on young
infants from our analysis. In the meta-analysis per-
formed by Beaton et al., the age attribution of deaths
for the MADURAI study (which contributed 425 out
of the 986 young infants used in the analysis) was
based on age at entry into the trial. For the present
meta-analysis, the principal investigators agreed to
re-examine the data, and re-analysed the findings
based on the actual age at death, as in the protocol.
Furthermore, valuable additional data on young
infants became available from one of the mortality
studies (SARLAHI). In our analysis, the impact on
all-cause mortality among 6-1 l-month-olds was
similar to that among older children, but the limited
data available from children aged under 6 months
who were supplemented with 50 000 or 100 000 IU
of vitamin A did not suggest the same protective
effect on all-cause mortality in this age group. Pneu-
monia is the largest contributor to deaths among
under-6-month-olds, and the absence of an impact
on pneumonia for this age group might provide an
explanation for the apparent lack of an impact of
vitamin A supplements on all-cause mortality among
young infants.
The finding that vitamin A supplementation
reduces the risk of death due to diarrhoea and mea-
sles, but not deaths due to nonmeasles-associated
pneumonia is somewhat surprising. Histopatho-
logical evidence suggests that the epithelial changes
following vitamin A depletion are more marked
in the respiratory tract than in the gastr-ointes-
tinal tract (1). It is also inconsistent with the findings
of observational studies that children who were
vitamin-A deficient had an increased risk of respira-
tory morbidity (10-12). Furthermore, a strong relation-
ship between VAD and severity of respiratory infec-
tions has been demonstrated in clinical studies:
administering vitamin A to children with measles
reduces the duration and severity of illness, the
incidence of complications, case fatality rates, and
subsequent morbidity from ARI (13-16). Vitamin A
supplementation also has had a significant positive
impact on respiratory infections among some high-risk
groups, e.g., low-birth-weight infants (27) and children
with a history of frequent respiratory illness (28).
d See footnote a, p. 611.
JUMLA is the only study in the present meta-
analysis that reported a reduction in the incidence of
pneumonia following vitamin A supplementation, but
it is significant that including or excluding the data
from JUMLA did not significantly alter the summary
estimate of the impact on pneumonia incidence:
the ratio remained close to unity. It appears therefore
that vitamin A supplementation has no overall
impact on pneumonia incidence, as defined by
cough and a measured increase in respiratory rate
using age-specific cut-offs, or by maternally reported
symptoms. This is consistent with the absence of an
impact on pneumonia mortality.
The results from the MORVITA and DELHI
studies indicate, however, a possible increase in the
risk of ARI symptoms among children receiving
vitamin A. In the HAITI study, the 2-week preva-
lence of respiratory symptoms, such as cough, rhin-
itis and rapid breathing, was slightly higher among
children receiving vitamin A compared with those
receiving placebo (25). In the meta-analysis, four out
of the nine studies that contributed data on the preva-
lence of coughing showed a 5-10% excess of cough-
ing among the vitamin-A-supplemented group. In
view of the high incidence of ARI morbidity in
infancy, such small increases in risk could corres-
pond to a large population impact, and these results
therefore merit further study.
Our findings have important implications for the
safety and efficacy of two proposed approaches to
vitamin A supplementation in young children in
areas where xerophthalmia is a public health prob-
lem - supplementation linked with vaccination con-
tacts and with clinic visits for illness. Despite the
apparent lack of an impact on pneumonia morbidity
and mortality, the accumulated data indicate that
there is a net benefit to giving vitamin A supple-
ments to children aged >6 months. Although pneu-
monia makes a very significant contribution to the
mortality burden in this age group, there are other
causes of death, such as measles and diarrhoea,
which also contribute to the mortality burden, and
vitamin A has proven efficacy in reducing such
deaths. In areas where VAD is a significant public
health problem, vitamin A supplements should be
given to children aged .6 months either through
community-based distribution programmes or through
contacts with the health service. Opportunities for
supplementation through the health services include
well-baby-clinic visits, sick-child visits, and EPI
contacts (the WHO-EPI 6-month plus recommenda-
tions), or special periodic mass supplementation
exercises. Vitamin A has also been shown to reduce
measles-associated pneumonia deaths and should be
administered to children with measles.
WHO Bulletin OMS. Vol 731995 617
Vitamin A and Pneumonia Working Group
Resume
Interventions possibles en vue de la
prevention de la pneumonie infantile dans
les pays en developpement: meta-analyse
des resultats d'essais pratiques visant a
evaluer l'effet de la supplementation en
vitamine A sur la morbidite et la mortalite
associees a la pneumonie
Cet article etudie 1'effet de la distribution de sup-
plements de vitamine A sur la morbidite et la mor-
talite associees a la pneumonie grace a une
meta-analyse des donnees recueillies jusqu'en
janvier 1993 dans 12 essais pratiques a grande
6chelle mends dans sept pays. Cefte etude s'ins-
crit dans un projet plus large d'evaluation des
possibilites de pr6vention de la pneumonie chez
1'enfant.
Cinq etudes ont fourni des informations rela-
tives a 1'effet des supplements de vitamine A sur
l'incidence des pneumonies. Si l'on considere ces
etudes individuellement, une seule (Jumia, Nepal)
revele un effet significatif (taux relatif (RR) =
0,77). Pour les autres etudes, les taux relatifs
varient de 0,92 a 1,14. Globalement, les donnees
n'indiquent aucun effet positif ou negatif sur l'inci-
dence des pneumonies. Le taux relatif global cal-
cule pour 1'ensemble des etudes est de 0,95
(intervalle de confiance (IC a 95% = 0,89-1,01),
ou 0,99 (IC a 95% = 0,92-1,06) si l'on exclut les
donnees de l'etude de Jumia.
Dans les cinq 6tudes ou l'on trouve des don-
nees sur les causes de mortalite, le risque relatif
combine de mortalite par pneumonie est de 0,98
(IC a 95% = 0,75-1,28). Ce r6sultat contraste net-
tement avec 1'effet appr6ciable des supplements
de vitamine A sur la mortalite toutes causes
confondues (RR combine = 0,77; IC a 95% =
0,71-0,84) et avec leur effet d6montre sur la mor-
talite due a la diarrhee et a la rougeole.
Aucune difference en fonction de I'fge n'a ete
mise en evidence en ce qui concerne l'effet sur la
mortalite attribuable a la pneumonie. Etant donn6
que la majorite des d6ces par pneumonie, soit
environ 75%, surviennent dans la premiere ann6e
de la vie, il a e procede a un examen d6taiII de
toutes les causes de mortalite chez les nourrissons
pour pallier la raret6 des donnees sur la mortalit6
par pneumonie dans cette tranche d'age. La reduc-
tion de la mortalit6 entre 6 et 11 mois correspond a
celle observee chez les enfants plus ages (RR =
0,69; IC a 95% = 0,54 a 0,90), mais il n'y a eu
aucune r6duction dans la tranche de 0 a 5 mois
(RR = 0,97; IC a 95% = 0,73-1,29). L'absence
d'impact des suppl6ments de vitamine A au cours
des six premiers mois de la vie est en accord avec
I'absence d'effet que nous avons observee sur les
deces dus a la pneumonie, principale cause de
mortalite dans cette tranche d'age.
S'il est prouve que I'administration de supple-
ments de vitamine A r6duit le risque de deces
chez les enfants ages de six mois et plus, elle est
inefficace pour la prevention des ddc&s dus a la
pneumonie et ne presente aucun avantage de-
montre dans la petite enfance. D'autres m6thodes
de prevention sont necessaires dans ce cas.
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